| abstract |
An object of the present invention is to provide an effective and safe mucosal vaccine adjuvant. More specifically, an object of the present invention is to provide an effective and safe adjuvant for mucosal vaccines without using bacterial toxins such as cholera toxin. By an adjuvant for mucosal vaccine comprising IL-33. Mucosal vaccine adjuvant of the present invention, when used with the transmucosal infectious pathogen-derived antigens, induced good IgG, and the IgG 1 and IgG 2a antibody that is each isotype efficiency. Furthermore, even when IL-33 is administered intranasally, antigen-specific IgA is secreted on the whole body mucosal surface such as the oral cavity, vagina and intestinal mucosa, and can be said to be an excellent mucosal vaccine adjuvant. [Selection] Figure 3 |